An anti-VEGF injection is an intravitreal treatment that blocks vascular endothelial growth factor, a key driver of abnormal, leaky blood vessels in the retina. It is a mainstay therapy for several sight-threatening retinal conditions.
Conditions Treated
Anti-VEGF drugs are used for wet age-related macular degeneration, diabetic macular oedema, some retinal vein occlusions, and other causes of macular swelling or neovascularisation. Regular injections aim to stabilise or improve central vision by reducing leakage and swelling.
- Treatment regimens vary from fixed monthly dosing to “treat-and-extend” schedules
- OCT scans and vision tests guide timing of repeat injections
- Many patients require long-term, intermittent therapy
- Stopping injections too early may risk recurrent fluid and vision loss
Procedure and Safety
The eye is cleaned with antiseptic, numbed with drops, and a fine needle delivers the medicine through the white of the eye into the vitreous cavity. The procedure is brief and usually well tolerated.
- Common transient effects include mild irritation, floaters, or redness
- Serious complications such as infection or retinal detachment are rare but need urgent attention
- Patients receive clear instructions about warning symptoms and follow-up
- Systemic safety is monitored, particularly in those with cardiovascular risk factors
